Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

Johnson & Johnson is challenging a federal health agency for blocking its plan to discount drugs through a rebate model ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...

now the second-largest federal drug initiative after Medicare, has been exploited by entities not intended initially as ...

Walgreens Boots Alliance has a storied history in Chicago, starting with a single retail outlet in 1901, and expanding across ...

NEW ORLEANS (WVUE) - If you have trouble affording prescription drugs, some independent pharmacists say that so-called ...

Consider one practice that illustrates the problem before Congress: PBMs aggressively negotiate large rebates from drug companies. These rebates dramatically cut insurance companies’ costs for ...

Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) ...